In recent years, PSMA-targeted PET/CT (using, e.g., [68Ga]Ga-PSMA-11) has gained increasing importance in the management of prostate cancer for initial staging, biochemical recurrence, and screening for PSMA-RLT [22–24]. Here, FOLH1 is linked to prostate cancer.